Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies
References
- Seltzer JH Gintant G Amiri-Kordestani L Assessing cardiac safety in oncology drug development Am Heart J 2019 Aug 214 125 33
- American Cancer Society [Internet] Atlanta, GA American Cancer Society c2019 Cancer Facts and Figures 2019; 2019 [cited 2019 Aug 15]. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html
- Cameron D Piccart-Gebhart MJ Gelber RD Herceptin Adjuvant (HERA) Trial Study Team 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Lancet 2017 Mar 25 389 10075 1195 205
- Piccart-Gebhart MJ Procter M Leyland-Jones B Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 2005 Oct 20 353 16 1659 72
- Romond EH Perez EA Bryant J Trastuzumab plus adjuvant chemo-therapy for operable HER2-positive breast cancer N Engl J Med 2005 Oct 20 353 16 1673 84
- Perez EA Rodeheffer R Clinical cardiac tolerability of trastuzumab J Clin Oncol 2004 Jan 15 22 2 322 9
- Kenigsberg B Jain V Barac A Cardio-oncology Related to Heart Failure: Epidermal Growth Factor Receptor Target-Based Therapy Heart Fail Clin 2017 Apr 13 2 297 309
- Barish R Gates E Barac A Trastuzumab-Induced Cardiomyopathy Cardiol Clin 2019 Nov 37 4 407 418
- Slamon DJ Leyland-Jones B Shak S Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 2001 Mar 15 344 11 783 92
- Seidman A Hudis C Pierri MK Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 2002 Mar 1 20 5 1215 21
- Kenigsberg B Wellstein A Barac A Left Ventricular Dysfunction in Cancer Treatment: Is it Relevant? JACC Heart Fail 2018 Feb 6 2 87 95
- Ewer SM Ewer MS Cardiotoxicity profile of trastuzumab Drug Saf 2008 31 6 459 67
- Nemeth BT Varga ZV Wu WJ Pacher P Trastuzumab cardiotoxicity: from clinical trials to experimental studies Br J Pharmacol 2017 Nov 174 21 3727 48
- Lemmens K Segers VF Demolder M De Keulenaer GW Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk J Biol Chem 2006 Jul 14 281 28 19469 77
- Clerk A Michael A Sugden PH Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy? J Cell Biol 1998 Jul 27 142 2 523 35
- Suter TM Procter M van Veldhuisen DJ Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial J Clin Oncol 2007 Sep 1 25 25 3859 65
- Linschoten M Teske AJ Cramer MJ van der Wall E Asselbergs FW Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk Circ Genom Precis Med 2018 Jan 11 1 e001753
- García-Rivello H Taranda J Said M Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle Am J Physiol Heart Circ Physiol 2005 Sep 289 3 H1153 60
- Ozcelik C Erdmann B Pilz B Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy Proc Natl Acad Sci U S A 2002 Jun 25 99 13 8880 5
- Crone SA Zhao YY Fan L ErbB2 is essential in the prevention of dilated cardiomyopathy Nat Med 2002 May 8 5 459 65
- Cote GM Sawyer DB Chabner BA ERBB2 inhibition and heart failure N Engl J Med 2012 Nov 29 367 22 2150 3
- Mohan N Shen Y Endo Y ElZarrad MK Wu WJ Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes Mol Cancer Ther 2016 Jun 15 6 1321 31
- Jiang J Mohan N Endo Y Shen Y Wu WJ Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity Oncotarget 2017 Dec 21 9 5 6095 108
- Armenian SH Lacchetti C Barac A Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 2017 Mar 10 35 8 893 911
- Barish R Lynce F Unger K Barac A Management of Cardiovascular Disease in Women With Breast Cancer Circulation 2019 Feb 19 139 8 1110 1120
- Barac A Quo Vadis Trastuzumab?: Navigating Cardiac Safety Risk Estimates With Complex Cancer Treatments JACC Heart Fail 2019 Mar 7 3 225 227
- Barac A Blaes A Lynce F Lessons From Primary Cardiac Prevention Trials During Trastuzumab Therapy: End of One Size Fits All J Am Coll Cardiol 2019 Jun 11 73 22 2869 2871
- Lynce F Barac A Geng X Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study Breast Cancer Res Treat 2019 Jun 175 3 595 603
- Leong DP Cosman T Alhussein MM Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity A Phase I Trial 2019 1 1 1 10
- Baselga J Cortés J Kim SB CLEOPATRA Study Group Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 2012 Jan 12 366 2 109 19
- Geyer CE Forster J Lindquist D Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 2006 Dec 28 355 26 2733 43
- Perez EA Koehler M Byrne J Preston AJ Rappold E Ewer MS Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials Mayo Clin Proc 2008 Jun 83 6 679 86
- Verma S Miles D Gianni L EMILIA Study Group Trastuzumab emtansine for HER2-positive advanced breast cancer N Engl J Med 2012 Nov 8 367 19 1783 91
- Chen MH Kerkela R Force T Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics Circulation 2008 Jul 1 118 1 84 95
- Barac A Yet another player in the cardio-oncology conundrum?: deciphering the role of FLT3 J Am Coll Cardiol 2014 Mar 18 63 10 1020 1
- Campia U Moslehi JJ Amiri-Kordestani L Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association Circulation 2019 Mar 26 139 13 e579 e602
- Touyz RM Herrmann J Cardiotoxicity with vascular endothelial growth factor inhibitor therapy NPJ Precis Oncol 2018 May 8 2 13
- Jang S Zheng C Tsai HT Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma Cancer 2016 Jan 1 122 1 124 30
- Abdel-Qadir H Ethier JL Lee DS Thavendiranathan P Amir E Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis Cancer Treat Rev 2017 Feb 53 120 127
- Chu TF Rupnick MA Kerkela R Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 2007 Dec 15 370 9604 2011 9
- Di Lorenzo G Autorino R Bruni G Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis Ann Oncol 2009 Sep 20 9 1535 42
- Maitland ML Bakris GL Black HR Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors J Natl Cancer Inst 2010 May 5 102 9 596 604
- Steingart RM Bakris GL Chen HX Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors Am Heart J 2012 Feb 163 2 156 63
- Grandin EW Ky B Cornell RF Carver J Lenihan DJ Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma J Card Fail 2015 Feb 21 2 138 44
- Cole DC Frishman WH Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma Cardiol Rev 2018 May/Jun 26 3 122 9
- Hasinoff BB Patel D Wu X Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib Cardiovasc Toxicol 2017 Jul 17 3 237 50
- Richardson PG Sonneveld P Schuster MW Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 2005 Jun 16 352 24 2487 98
- Siegel D Martin T Nooka A Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies Haematologica 2013 Nov 98 11 1753 61
- Siegel DS Martin T Wang M A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Blood 2012 Oct 4 120 14 2817 25
- Varricchi G Galdiero MR Marone G Cardiotoxicity of immune checkpoint inhibitors ESMO Open 2017 Oct 26 2 4 e000247
- Boutros C Tarhini A Routier E Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination Nat Rev Clin Oncol 2016 Aug 13 8 473 86
- Johnson DB Balko JM Compton ML Fulminant Myocarditis with Combination Immune Checkpoint Blockade N Engl J Med 2016 Nov 3 375 18 1749 55
- Jain V Mohebtash M Rodrigo ME Ruiz G Atkins MB Barac A Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin J Immunother 2018 Sep 41 7 332 5
- Lyon AR Yousaf N Battisti NML Moslehi J Larkin J Immune checkpoint inhibitors and cardiovascular toxicity Lancet Oncol 2018 Sep 19 9 e447 e458
- Jain V Bahia J Mohebtash M Barac A Cardiovascular Complications Associated With Novel Cancer Immunotherapies Curr Treat Options Cardiovasc Med 2017 May 19 5 36
- Mahmood SS Fradley MG Cohen JV Myocarditis in Patients Treated With Immune Checkpoint Inhibitors J Am Coll Cardiol 2018 Apr 24 71 16 1755 64
DOI: https://doi.org/10.14797/mdcj-15-4-250 | Journal eISSN: 1947-6108
Language: English
Page range: 250 - 257
Published on: Oct 1, 2019
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2019 Tolulope A. Agunbiade, Raja Y. Zaghlol, Ana Barac, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.